(Q35825923)

10 August 2017

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany (English)

1 reference

10 August 2017

0 references

0 references

1 reference

corrigendum / erratum

1 reference

10.1177/1756285612445143

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1177/1756285612445143

9

Frauke Zipp

0 references

Andreas Ziegler

object named as

Andreas Ziegler

12

0 references

Bernd C Kieseier

11

object named as

Bernd C Kieseier

1 reference

10 August 2017

13

Ralf Gold

1 reference

10 August 2017

Anke Stroet

1

1 reference

10 August 2017

Claudia Hemmelmann

2

1 reference

10 August 2017

Michaela Starck

3

1 reference

10 August 2017

Uwe Zettl

4

1 reference

10 August 2017

Jan Dörr

5

1 reference

10 August 2017

Paul Friedemann

6

1 reference

10 August 2017

Peter Flachenecker

7

1 reference

10 August 2017

Vinzenz Fleischer

8

1 reference

10 August 2017

Holger Nückel

10

1 reference

10 August 2017

Andrew Chan

14

1 reference

10 August 2017

1 March 2012

1 reference

Therapeutic advances in neurological disorders

10 August 2017

1 reference

10 August 2017

5

1 reference

10 August 2017

2

1 reference

10 August 2017

75-79

1 reference

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302202

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302202

Multiple sclerosis registry in Germany: results of the extension phase 2005/2006

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302202

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302202

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302202

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302202

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302202

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22435072

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1756285611433318

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22435072

1 reference